Prelude Therapeutics Presents Strong Preclinical Data for Lead Cancer Candidate PRT13722
PRLD has more than doubled off its 52-week low of $0.72.
Summary
Prelude Therapeutics presented strong preclinical data for its lead cancer candidate, PRT13722, showing durable tumor regressions and an improved safety profile, with an IND filing expected mid-2026.
Key Events · Product Development and Regulatory · PRLD
-
Preclinical Data Presentation
Prelude Therapeutics presented new preclinical data for PRT13722, a lead development candidate for HR+/HER2- breast cancer, at the AACR Annual Meeting 2026.
-
Strong Efficacy Profile
PRT13722 demonstrated durable complete tumor regressions as a monotherapy in xenograft models and synergistic activity with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.
-
Improved Safety Profile
The data indicated an improved preclinical hematological safety profile for PRT13722 compared to dual KAT6A/B inhibitors like prifetrastat.
-
Advancing to Clinic
The company remains on track for an Investigational New Drug (IND) filing in mid-2026, with a Phase 1 study anticipated in the second half of 2026.
Analysis · PRLD · Life Sciences
Prelude Therapeutics announced compelling preclinical data for PRT13722, its lead development candidate for HR+/HER2- breast cancer, at the AACR Annual Meeting. The data highlights PRT13722's potential as a first-in-class, highly selective KAT6A degrader, demonstrating durable complete tumor regressions as a monotherapy and synergistic activity with standard-of-care agents. Crucially, it shows an improved safety profile compared to existing inhibitors, addressing a key challenge in cancer therapy. This positive update significantly de-risks the program as the company prepares for an IND filing in mid-2026 and Phase 1 study initiation in the second half of 2026, reinforcing its pipeline strength and future growth prospects in a large market.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRLD was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $279.7M. The 52-week trading range was $0.72 to $5.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.